Atea appoints Howard Berman to board, authorizes $25M buyback after activist settlement

Atea Pharmaceuticals, Inc.

Howard H. Berman (Coya Therapeutics founder) appointed as Class III director effective after 2025 annual meeting; will serve as observer until then.
Agreement with activist investors Bradley Radoff and Michael Torok: slate withdrawn, standstill and voting commitments through mid-2026.
Franklin Berger will retire from board after his Class I term expires at 2027 annual meeting.
Board authorized up to $25M share repurchase program; strategic alternatives review with Evercore ongoing.
Preliminary cash, cash equivalents and marketable securities as of March 31, 2025: $425.4 million.

item 1.01 item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Howard H. Berman

Class III director

AVIR · Atea Pharmaceuticals, Inc.

Filed: April 17, 2025, 7:59 PM ET

On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Effective Time.

Departed

Franklin Berger

Class I director

AVIR · Atea Pharmaceuticals, Inc.

Filed: April 17, 2025, 7:59 PM ET

In addition, on April 16, 2025, in connection with the Agreement, Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Howard H. Berman was appointed as Class III director at Atea Pharmaceuticals, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Effective Time.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Franklin Berger departed as Class I director at Atea Pharmaceuticals, Inc..

Action: retire
Role: Class I director

Exact text from the filing

In addition, on April 16, 2025, in connection with the Agreement, Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.

View on SEC.gov

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-083523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.